![]() |
市場調查報告書
商品編碼
2176427
自動化細胞和基因治療生產系統市場預測至2034年—按產品類型、治療類型、技術、應用、最終用戶和地區分類的全球分析Automated Cell and Gene Therapy Manufacturing Systems Market Forecasts to 2034 - Global Analysis By Product Type, Therapy Type, Technology, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球自動化細胞和基因治療製造系統市場預計將在 2026 年達到 18 億美元,並在預測期內以 20.3% 的複合年成長率成長,到 2034 年達到 79 億美元。
自動化細胞和基因治療生產系統市場涵蓋了先進的製造解決方案,這些方案整合了機器人自動化、封閉式細胞處理、生物反應器和智慧過程監控,從而支持細胞和基因療法的規模化生產。對個人化醫療日益成長的需求、不斷擴展的臨床研發管線以及對先進治療產品製造投入的增加,正在推動市場成長。自動化細胞增殖、基因修飾和品管技術的整合提高了生產的一致性和營運效率。先進治療產品的商業化為整合式製造平台創造了機會。
對可擴展和標準化的細胞和基因治療生產的需求日益成長。
對可擴展和標準化的細胞和基因治療生產的需求日益成長,正在推動市場成長。製藥和生物技術公司正在擴大產能,以滿足不斷成長的臨床研發管線和先進療法的商業化需求。傳統的手工生產流程一直飽受勞動密集、操作複雜和批次間差異大的困擾。自動化系統能夠提高製程一致性,降低污染風險,並有助於創造可控的生產環境。封閉式細胞處理、自動化生物反應器和數位化製程監控技術的進步,正在進一步加速這些技術在細胞和基因治療生產設施中的應用。
大量資本投資和自動化製造系統的複雜整合
高昂的資本投入和自動化生產系統的複雜整合正在阻礙市場成長。細胞和基因治療生產平台需要專用設備、檢驗的製程和受控的生產環境,這推高了實施成本。治療產品、細胞來源和生產方案的差異使得不同設施間的標準化變得困難。製程驗證、品質保證和生產文件方面的監管要求也帶來了進一步的挑戰。熟練人員的短缺以及將自動化設備與現有生產基礎設施整合的困難可能會進一步延緩小規模生物技術公司採用該技術。
擴大同種異體和分散細胞治療生產
異體療法和分散式細胞療法生產的擴展帶來了巨大的成長機會。生物技術公司正在開發高度擴充性的「現成」細胞療法生產流程,這些工藝需要穩定的生產和高效的批量處理。自動化、封閉式系統平台可以支援分散式生產設施,並減少對集中式生產基礎設施的依賴。對模組化生產系統、機器人自動化和數位化品質監控的投資增加正在推動創新。自動化細胞增殖、非病毒基因轉移和整合製程分析的進步有望加速整個先進治療藥物生產網路的商業化。
監理合規風險與製造流程變異性
監理合規風險和生產製程變異性對市場開發構成重大挑戰。自動化細胞和基因治療生產系統必須在複雜的生物過程中維持產品的特性、純度、效力和一致性。設備故障、軟體錯誤或製程控制不足都可能影響治療產品的品質和生產的連續性。監管預期和先進療法標準的差異會使平台驗證變得複雜。除了與成熟的手動和半自動化生產方法競爭外,療法商業化的不確定性也會進一步限制投資和應用。
新冠疫情透過供應鏈中斷、實驗室活動受限和臨床開發延誤,擾亂了細胞和基因療法的生產。取得專用材料、生產設備和熟練人員的困難影響了生產計劃和設施運作。然而,疫情凸顯了具有韌性的生物製造基礎設施的重要性,並加速了人們對自動化、遠端監控和封閉式系統處理技術的興趣。對生物技術製造和數位化生產系統的投資增加,為復甦提供了支持。疫情後,對可擴展和靈活的治療藥物生產的關注,推動了自動化平台的持續應用。
在預測期內,自動化細胞處理系統細分市場預計將佔據最大的市場佔有率。
鑑於整個細胞治療生產流程中對細胞分離、洗滌、濃縮和製備的廣泛需求,預計在預測期內,自動化細胞處理系統細分市場將佔據最大的市場佔有率。製藥公司和生物技術製造商正擴大採用自動化處理平台,以減少人力並提高生產一致性。自體細胞療法和基因修飾細胞療法的商業化也推動了這項需求。封閉式系統處理、整合流體處理和標準化生產流程的進步,進一步增強了該細分市場在先進治療藥物生產設施中的成長。
預計在預測期內,整合式端到端製造系統細分市場將呈現最高的複合年成長率。
在預測期內,整合式端到端製造系統細分市場預計將呈現最高的成長率,這主要得益於對全自動、可擴展的細胞治療生產流程日益成長的需求。整合平台將細胞分離、活化、增殖、基因修飾和最終產品加工整合於受控的生產環境中。對商業規模細胞和基因治療生產的投資增加正在推動其應用。機器人操作、數位化製程控制和模組化製造架構的進步有望提高營運效率,並加速生物技術製造設施的採用。
在整個預測期內,北美預計將保持最大的市場佔有率,這得益於其完善的生物技術基礎設施、大量的製藥投資以及細胞和基因治療領域的顯著進步。美國正透過先進的治療藥物生產商、合約開發組織 (CDO) 和專業研究機構來推動該地區的市場應用。對商業生產設施和自動化生產技術的投資增加也促進了市場擴張。生物技術公司、設備製造商和研究機構之間的合作進一步增強了該地區對整合式細胞和基因治療生產系統的需求。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於生物技術製造能力的擴張、對先進療法投資的增加以及自動化生產技術的日益普及。中國、日本、韓國和印度正在大力發展細胞療法研究和生物製造基礎設施。對高度擴充性的生產系統和標準化品管日益成長的需求正在推動技術的應用。政府支持的生物技術計劃以及製藥公司、設備製造商和契約製造組織(CMO)之間的夥伴關係預計將加速該地區的市場成長。
According to Stratistics MRC, the Global Automated Cell and Gene Therapy Manufacturing Systems Market is accounted for $1.8 billion in 2026 and is expected to reach $7.9 billion by 2034 growing at a CAGR of 20.3% during the forecast period. The Automated Cell and Gene Therapy Manufacturing Systems Market encompasses advanced manufacturing solutions that integrate robotic automation, closed-system cell processing, bioreactors, and intelligent process monitoring to support scalable production of cell and gene therapies. Increasing demand for personalized treatments, expanding clinical pipelines, and growing investment in advanced therapy manufacturing are supporting market growth. Integration of automated cell expansion, genetic modification, and quality control technologies improves manufacturing consistency and operational efficiency. Growing commercialization of advanced therapeutic products creates opportunities for integrated manufacturing platforms.
Increasing demand for scalable and standardized cell and gene therapy manufacturing
Increasing demand for scalable and standardized cell and gene therapy manufacturing is driving market growth. Pharmaceutical and biotechnology companies are expanding production capabilities to support growing clinical pipelines and commercialization of advanced therapies. Conventional manual manufacturing processes involve extensive labor, operational complexity, and variability between production batches. Automated systems improve process consistency, reduce contamination risks, and support controlled manufacturing environments. Advancements in closed-system cell processing, automated bioreactors, and digital process monitoring further strengthen adoption across cell and gene therapy production facilities.
High capital investment and complex integration of automated manufacturing systems
High capital investment and complex integration of automated manufacturing systems restrain market growth. Cell and gene therapy manufacturing platforms require specialized equipment, validated processing workflows, and controlled production environments, increasing implementation expenses. Differences in therapeutic products, cell sources, and manufacturing protocols complicate standardization across facilities. Regulatory requirements for process validation, quality assurance, and manufacturing documentation create additional challenges. Limited availability of skilled personnel and difficulties integrating automated equipment with existing production infrastructure may further delay adoption among smaller biotechnology companies.
Expansion of allogeneic therapies and decentralized cell therapy manufacturing
Expansion of allogeneic therapies and decentralized cell therapy manufacturing presents significant growth opportunities. Biotechnology companies are developing scalable manufacturing processes for off-the-shelf cell therapies that require consistent production and efficient batch processing. Automated closed-system platforms can support distributed manufacturing facilities and reduce dependence on centralized production infrastructure. Growing investment in modular manufacturing systems, robotic automation, and digital quality monitoring encourages innovation. Advancements in automated cell expansion, non-viral gene delivery, and integrated process analytics are expected to accelerate commercialization across advanced therapy manufacturing networks.
Regulatory compliance risks and manufacturing process variability
Regulatory compliance risks and manufacturing process variability pose significant challenges to market development. Automated cell and gene therapy manufacturing systems must maintain product identity, purity, potency, and consistency across complex biological processes. Equipment failures, software errors, or inadequate process controls may affect therapeutic product quality and manufacturing continuity. Differences in regulatory expectations and evolving standards for advanced therapies can complicate platform validation. Competition from established manual and semi-automated manufacturing approaches, alongside uncertainty regarding therapy commercialization, may further restrict investment and adoption.
The COVID-19 pandemic disrupted cell and gene therapy manufacturing through supply chain interruptions, laboratory restrictions, and delays in clinical development activities. Limited availability of specialized materials, manufacturing equipment, and skilled personnel affected production schedules and facility operations. However, the pandemic highlighted the importance of resilient biomanufacturing infrastructure and accelerated interest in automation, remote monitoring, and closed-system processing technologies. Growing investment in biotechnology manufacturing and digital production systems supported recovery. Post-pandemic emphasis on scalable and flexible therapeutic manufacturing has encouraged continued adoption of automated platforms.
The automated cell processing systems segment is expected to be the largest during the forecast period
The automated cell processing systems segment is expected to account for the largest market share during the forecast period due to widespread requirements for cell isolation, washing, concentration, and preparation across cell therapy manufacturing workflows. Pharmaceutical companies and biotechnology manufacturers increasingly adopt automated processing platforms to reduce manual handling and improve production consistency. Growing commercialization of autologous and gene-modified cell therapies supports equipment demand. Advancements in closed-system processing, integrated fluid handling, and standardized manufacturing protocols further strengthen segment growth across advanced therapy production facilities.
The integrated end-to-end manufacturing systems segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the integrated end-to-end manufacturing systems segment is predicted to witness the highest growth rate due to increasing demand for fully automated and scalable cell therapy production workflows. Integrated platforms combine cell isolation, activation, expansion, genetic modification, and final product processing within coordinated manufacturing environments. Growing investment in commercial-scale cell and gene therapy production encourages adoption. Advancements in robotic handling, digital process control, and modular manufacturing architectures are expected to improve operational efficiency and accelerate deployment across biotechnology manufacturing facilities.
During the forecast period, North America is expected to hold the largest market share due to established biotechnology infrastructure, substantial pharmaceutical investment, and strong development of cell and gene therapies. The United States leads regional adoption through advanced therapy manufacturers, contract development organizations, and specialized research institutions. Growing investment in commercial manufacturing facilities and automated production technologies supports market expansion. Collaboration among biotechnology companies, equipment manufacturers, and research organizations further strengthens regional demand for integrated cell and gene therapy manufacturing systems.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding biotechnology manufacturing capabilities, increasing investment in advanced therapies, and growing adoption of automated production technologies. China, Japan, South Korea, and India are advancing cell therapy research and biomanufacturing infrastructure. Increasing demand for scalable production systems and standardized quality control encourages technology deployment. Government-supported biotechnology initiatives and partnerships among pharmaceutical companies, equipment manufacturers, and contract manufacturing organizations are expected to accelerate regional market growth.
Key players in the market
Some of the key players in the Automated Cell and Gene Therapy Manufacturing Systems Market include Miltenyi Biotec B.V. & Co. KG, Thermo Fisher Scientific Inc., Cytiva, Sartorius AG, Terumo Blood and Cell Technologies, Cellares Corporation, Ori Biotech Ltd., Multiply Labs, Inc., Cellular Origins, ADVA Biotechnology Ltd., Orgenesis Inc., Fresenius Kabi AG, Bio-Techne Corporation, Wilson Wolf Manufacturing Corporation, Eppendorf SE, Hamilton Company, Beckman Coulter Life Sciences, and Lonza Group AG.
In October 2026, Ori Biotech Ltd. announced that Catalent had joined its Preferred Partner Network, establishing Catalent's Princeton facility as a Center of Excellence for the IRO automated manufacturing platform. The collaboration supports autologous cell therapy process development and GMP manufacturing.
In September 2026, Cellares Corporation partnered with Seoul National University Hospital to evaluate automated manufacturing of gene-modified hematopoietic stem and progenitor cell therapies using its Cell Shuttle platform. The collaboration targets manufacturing development for a potential treatment of paroxysmal nocturnal hemoglobinuria.
In September 2025, Lonza Group AG's Cocoon automated cell therapy manufacturing platform received FDA Advanced Manufacturing Technology designation, supporting the development of standardized and scalable cell therapy manufacturing processes.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.